Artiva Biotherapeutics 過去の業績
過去 基準チェック /06
Artiva Biotherapeutics's earnings have been declining at an average annual rate of -7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 92.1% per year.
主要情報
-7.0%
収益成長率
-2.9%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | 92.1% |
| 株主資本利益率 | -128.5% |
| ネット・マージン | -111.2% |
| 前回の決算情報 | 30 Jun 2024 |
最近の業績更新
更新なし
収支内訳
Artiva Biotherapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 24 | 29 | -33 | 13 | 48 |
| 31 Mar 24 | 33 | -26 | 14 | 47 |
| 31 Dec 23 | 33 | -29 | 14 | 50 |
| 31 Mar 23 | 5 | -63 | 21 | 49 |
| 31 Dec 22 | 5 | -59 | 21 | 44 |
| 31 Mar 22 | 3 | -41 | 14 | 30 |
| 31 Dec 21 | 2 | -72 | 13 | 42 |
| 30 Sep 21 | 1 | -66 | 10 | 38 |
| 31 Dec 20 | 0 | -18 | 4 | 14 |
質の高い収益: ARTV is currently unprofitable.
利益率の向上: ARTV is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ARTV is unprofitable, and losses have increased over the past 5 years at a rate of 7% per year.
成長の加速: Unable to compare ARTV's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: ARTV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
株主資本利益率
高いROE: ARTV has a negative Return on Equity (-128.48%), as it is currently unprofitable.